[moreButton]
 Learn then Earn

 story : AstraZeneca COVID-19 vaccine may trigger 'very rare' nerve disease, European regulator says #FinanceUSA #StockMarketNEWS There's at least a "reasonable possibility" AstraZeneca's Vaxzevria COVID-19

@stockMarketNEWS 7 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

AstraZeneca COVID-19 vaccine may trigger 'very rare' nerve disease, European regulator says #FinanceUSA #StockMarketNEWS
There's at least a "reasonable possibility" AstraZeneca's Vaxzevria COVID-19 vaccine causes Guillain-Barré syndrome, a serious nerve inflammation which may cause temporary loss of feeling and movement and difficulty breathing, the European Medicines Agency said. The regulator called the frequency "very rare" -- as in less than 1 in 10,000 -- as it recommended GBS should be added as a side effect to the product information.


Munafa USA Munafa India Munafa NSE


Report

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme